GlassScriptPhysician profile
Adam Ryan Case
NPI 1477066637
$33,568.65
in general payments reported to CMS, 2019-2025
12 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $203 · 2023: $678 · 2024: $910 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,961 · Travel and Lodging: $1,762 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,900.00 |
| Food and Beverage | $2,960.90 |
| Travel and Lodging | $1,761.87 |
| Education | $119.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29,263.80 | 2024-2025 | Omvoh |
| Abbvie INC. | $1,458.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $969.50 | 2025 | |
| Janssen Biotech, INC. | $870.41 | 2021-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $467.36 | 2021-2025 | Tremfya |
| Celltrion USA INC. | $149.13 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $132.14 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $90.85 | 2025 | Entyvio, Eohilia |
| Pfizer INC. | $83.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.28 | 2024 | Xifaxan |
| Genzyme Corporation | $28.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.